Jove
Visualize
Contáctanos

Videos de Conceptos Relacionados

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

259
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
259
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

260
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
260
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

796
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
796
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

204
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
204
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

163
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
163
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

273
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
273

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Changes in Cardiac-Arterial Coupling After Cardiac Surgery for Aortic Valve Disease.

Reviews in cardiovascular medicine·2026
Same author

Genomic Medicine Sweden: Advancing precision medicine at the national level.

Journal of internal medicine·2026
Same author

Sex Differences in Clinical Outcomes and Loss of Life Expectancy After Aortic Valve Surgery for Infective Endocarditis: A SWEDEHEART Study.

Journal of the American Heart Association·2026
Same author

Oxylipin-mediated metabolic signatures of symbiosis homeostasis and thermal stress in a model sea anemone.

The ISME journal·2026
Same author

Ferroptosis promotes aortic stenosis through 5-lipoxygenase.

European heart journal·2026
Same author

LIPID MAPS: Powering discovery in lipidomics.

Science signaling·2026
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Video Experimental Relacionado

Updated: Dec 19, 2025

Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats
10:28

Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats

Published on: December 5, 2017

9.6K

Los ácidos grasos poliinsaturados omega-3 disminuyen la enfermedad de la válvula aórtica a través del eje Resolvin E1

Gonzalo Artiach1, Miguel Carracedo1, Oscar Plunde1

  • 1Department of Medicine (G.A., M.C., O.P., S.T., A.L.-F., H.A., M.B.), Karolinska Institutet, Stockholm, Sweden.

Circulation
|June 9, 2020
PubMed
Resumen
Este resumen es generado por máquina.

Los ácidos grasos omega-3 (n-3 PUFAs) y su mediador resolvin E1 inhiben la progresión de la estenosis de la válvula aórtica (AVS). Dirigirse a esta vía puede ofrecer nuevas opciones terapéuticas para el SAV.

Palabras clave:
Calcificación fisiológicaácidos grasos omega-3Enfermedades de las válvulas del corazóninflamaciónLos lípidos

Más Videos Relacionados

Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea
07:36

Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea

Published on: December 23, 2022

1.8K
Using En Face Immunofluorescence Staining to Observe Vascular Endothelial Cells Directly
06:09

Using En Face Immunofluorescence Staining to Observe Vascular Endothelial Cells Directly

Published on: August 20, 2019

16.5K

Videos de Experimentos Relacionados

Last Updated: Dec 19, 2025

Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats
10:28

Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats

Published on: December 5, 2017

9.6K
Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea
07:36

Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea

Published on: December 23, 2022

1.8K
Using En Face Immunofluorescence Staining to Observe Vascular Endothelial Cells Directly
06:09

Using En Face Immunofluorescence Staining to Observe Vascular Endothelial Cells Directly

Published on: August 20, 2019

16.5K

Área de la Ciencia:

  • Biología cardiovascular
  • La lipidomía
  • Investigación de la inflamación

Sus antecedentes:

  • La estenosis de la válvula aórtica (AVS) es la enfermedad cardíaca valvular más común, caracterizada por el engrosamiento y la calcificación de la válvula aórtica.
  • Los ácidos grasos poliinsaturados omega-3 (PUFA n-3) muestran beneficios cardiovasculares y son precursores de mediadores especializados en la proresolución con propiedades antiinflamatorias.
  • El papel de los PUFA n-3 y sus mediadores derivados en la patogénesis de la EVA sigue siendo en gran medida indeterminado.

Objetivo del estudio:

  • Investigar el papel de los mediadores proresolventes especializados derivados del PUFA n-3 en el desarrollo de la EVA.
  • Para determinar si la resolvina E1 influye en la calcificación de la válvula aórtica.

Principales métodos:

  • Análisis lipidómico y transcriptómico de las válvulas aórticas humanas.
  • Se utilizaron modelos de ratones Apoe y de heridas de alambre para estudios mecanicistas.
  • Se investigaron los efectos de la síntesis endógena de PUFA n-3 y la actividad del receptor de resolvina E1 (ChemR23).

Principales resultados:

  • La incorporación de PUFA n-3 fue mayor en las regiones no calcificadas que en las calcificadas de las válvulas estenóticas humanas.
  • Resolvin E1 se desreguló en las regiones calcificadas e inhibió la calcificación.
  • Los ratones con una mayor síntesis endógena de PUFA n-3 mostraron una reducción de la calcificación valvular y una mejora de la función cardíaca.
  • El bloqueo del receptor de resolvina E1 suprimió estos efectos beneficiosos.

Conclusiones:

  • La resolvina E1 derivada del PUFA n-3 y su eje receptor ChemR23 son cruciales para inhibir la progresión de la EVA.
  • Esta vía representa un nuevo objetivo terapéutico potencial para los pacientes con EVA.